Shilpa Medicare secures Europe approval for smoking cessation drug Varenicline

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-02-26T12:42:07+05:30 | Updated On 21 March 2024 3:41 PM IST

Parental Smoking and the Risk of Birth Defects in Offspring in China

Varenicline is indicated for smoking cessation in adults. It is used for quitting smoking.

Karnataka: Shilpa Medicare Limited has announced that the Company has received closure of Decentralized Procedure for Varenicline Tablets, 0.5 mg and 1 mg.

Commercial supplies shall be started after the approval of National Procedure. Varenicline is indicated for smoking cessation in adults. It is used for quitting smoking.

This product had sales of about 57 Million USD as of December 2021 prior to a decline in sales due to drug shortage due to post-production quality issues.

"This approval will enable Shilpa to make this quality medicine available to adults who intend to quit smoking and fill the drug shortage," the Company stated in a recent BSE filing.

Read also: Shilpa Medicare gets Germany marketing authorization for Amifampridine Tablets

Shilpa Medicare Limited started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of API and Formulation globally in different regulated markets.

shilpa medicareshipa medicare newsvarenicline tabletssmoking

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751